Published in Mol Genet Metab on August 11, 2011
The emerging phenotype of long-term survivors with infantile Pompe disease. Genet Med (2012) 1.39
Lysosomal storage diseases--the horizon expands. Nat Rev Neurol (2013) 1.15
Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT. PLoS One (2013) 1.14
CRIM-Negative Pompe Disease Patients with Satisfactory Clinical Outcomes on Enzyme Replacement Therapy. JIMD Rep (2012) 0.99
Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease. J Inherit Metab Dis (2014) 0.99
Letter to the Editors: Concerning "CRIM-negative Pompe disease patients with satisfactory clinical outcomes on enzyme replacement therapy" by Al Khallaf et al. J Inherit Metab Dis (2013) 0.89
CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapy. Genet Med (2015) 0.89
Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy. Orphanet J Rare Dis (2013) 0.88
Non-depleting anti-CD4 monoclonal antibody induces immune tolerance to ERT in a murine model of Pompe disease. Mol Genet Metab Rep (2014) 0.79
Pompe disease in adulthood: effects of antibody formation on enzyme replacement therapy. Genet Med (2016) 0.75
High dose IVIG successfully reduces high rhGAA IgG antibody titers in a CRIM-negative infantile Pompe disease patient. Mol Genet Metab (2017) 0.75
Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology (2006) 5.67
A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr (2006) 3.45
The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics (2003) 3.24
Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab (2010) 2.99
Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr (2006) 2.97
Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med (2009) 2.53
Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res (2009) 2.28
The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. Genet Med (2011) 2.08
Elimination of antibodies to recombinant enzyme in Pompe's disease. N Engl J Med (2009) 1.99
Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II. Mol Ther (2005) 1.88
Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I. J Clin Invest (2008) 1.70
CRIM-negative infantile Pompe disease: 42-month treatment outcome. J Inherit Metab Dis (2010) 1.51
Left ventricular myocardial mass determined by cross-sectional echocardiography in normal newborns, infants, and children. Pediatr Cardiol (1991) 1.25
Long-term monitoring of patients with infantile-onset Pompe disease on enzyme replacement therapy using a urinary glucose tetrasaccharide biomarker. Genet Med (2009) 1.22
Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder. Trends Mol Med (2003) 1.20
Immune response to enzyme replacement therapy in lysosomal storage disorder patients and animal models. Mol Genet Metab (1999) 1.13
Arrhythmias in patients receiving enzyme replacement therapy for infantile Pompe disease. Genet Med (2008) 0.92
The conservative substitution Asp-645-->Glu in lysosomal alpha-glucosidase affects transport and phosphorylation of the enzyme in an adult patient with glycogen-storage disease type II. Biochem J (1993) 0.90
Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood (2006) 3.85
Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood (2005) 3.63
A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J Med (2010) 3.05
Pompe disease diagnosis and management guideline. Genet Med (2006) 3.03
Population deworming every 6 months with albendazole in 1 million pre-school children in North India: DEVTA, a cluster-randomised trial. Lancet (2013) 2.95
Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med (2009) 2.53
The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. Genet Med (2011) 2.08
Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet Med (2012) 2.05
Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21). Blood (2006) 2.00
Elimination of antibodies to recombinant enzyme in Pompe's disease. N Engl J Med (2009) 1.99
Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease. Lab Invest (2006) 1.91
Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II. Mol Ther (2005) 1.88
Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II. Mol Ther (2005) 1.87
Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cells. Mol Genet Metab (2012) 1.79
Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance. Am J Hum Genet (2007) 1.76
WT1 mutations in T-ALL. Blood (2009) 1.75
Cardiac arrhythmias following anesthesia induction in infantile-onset Pompe disease: a case series. Paediatr Anaesth (2007) 1.64
Glycogen storage disease type III-hepatocellular carcinoma a long-term complication? J Hepatol (2006) 1.62
Deconstructing Pompe disease by analyzing single muscle fibers: to see a world in a grain of sand... Autophagy (2007) 1.60
The impact of antibodies in late-onset Pompe disease: a case series and literature review. Mol Genet Metab (2012) 1.60
Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa. Mol Genet Metab (2012) 1.58
Improvement of bilateral ptosis on higher dose enzyme replacement therapy in Pompe disease. J Neuroophthalmol (2010) 1.54
Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell populations cultured in fetal calf serum in mice and humans. Blood (2007) 1.52
Pompe disease: design, methodology, and early findings from the Pompe Registry. Mol Genet Metab (2011) 1.48
Quantitative assessment of lingual strength in late-onset Pompe disease. Muscle Nerve (2015) 1.43
Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J Immunol Methods (2007) 1.42
Prenatal diagnosis of Down syndrome: how best to deliver the news. Am J Med Genet A (2009) 1.40
The emerging phenotype of long-term survivors with infantile Pompe disease. Genet Med (2012) 1.39
Challenges in screening for hepatocellular carcinoma in the glycogen storage disease type 1a population. Intern Med (2012) 1.38
Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease. Mol Ther (2009) 1.34
High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa. Mol Genet Metab (2010) 1.32
Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease. Genet Med (2012) 1.31
Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease. Pediatrics (2004) 1.31
Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. Blood (2006) 1.30
Urea cycle disorders: clinical presentation outside the newborn period. Crit Care Clin (2005) 1.23
Peripheral expression of self-MHC-II influences the reactivity and self-tolerance of mature CD4(+) T cells: evidence from a lymphopenic T cell model. Immunity (2002) 1.22
Long-term monitoring of patients with infantile-onset Pompe disease on enzyme replacement therapy using a urinary glucose tetrasaccharide biomarker. Genet Med (2009) 1.22
Urinary biomarkers of oxidative status in a clinical model of oxidative assault. Cancer Epidemiol Biomarkers Prev (2010) 1.21
AAV vector-mediated reversal of hypoglycemia in canine and murine glycogen storage disease type Ia. Mol Ther (2008) 1.18
Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT. PLoS One (2013) 1.14
Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia. Br J Clin Pharmacol (2013) 1.14
Oropharyngeal dysphagia in infants and children with infantile Pompe disease. Dysphagia (2009) 1.13
Rare disorders of metabolism with elevated butyryl- and isobutyryl-carnitine detected by tandem mass spectrometry newborn screening. Pediatr Res (2003) 1.13
Autopsy findings in late-onset Pompe disease: a case report and systematic review of the literature. Mol Genet Metab (2012) 1.13
Electrocardiographic response to enzyme replacement therapy for Pompe disease. Genet Med (2006) 1.10
Donepezil for the treatment of language deficits in adults with Down syndrome: a preliminary 24-week open trial. Am J Med Genet A (2003) 1.10
Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience. Am J Med Genet C Semin Med Genet (2012) 1.09
Correction of multiple striated muscles in murine Pompe disease through adeno-associated virus-mediated gene therapy. Mol Ther (2008) 1.09
Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics. Genet Med (2014) 1.08
A modified model of graft-versus-host-induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease. Arthritis Rheum (2004) 1.07
Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial. Br J Haematol (2012) 1.07
How well does urinary lyso-Gb3 function as a biomarker in Fabry disease? Clin Chim Acta (2010) 1.06
Elevation of guanidinoacetate in newborn dried blood spots and impact of early treatment in GAMT deficiency. Mol Genet Metab (2013) 1.05
Minimal effects on immune parameters following chronic anti-TGF-beta monoclonal antibody administration to normal mice. Immunopharmacol Immunotoxicol (2003) 1.05
β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease. Mol Genet Metab (2011) 1.04
Validation of a HLA-A2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detection of immunologic response to gp100 and MelanA/MART-1 in melanoma patients. J Transl Med (2008) 1.02
Postnatal diagnosis of Down syndrome: synthesis of the evidence on how best to deliver the news. Pediatrics (2009) 1.02
The clinical and electrodiagnostic characteristics of Pompe disease with post-enzyme replacement therapy findings. Clin Neurophysiol (2011) 1.01
Protecting against antimicrobial effectors in the phagosome allows SodCII to contribute to virulence in Salmonella enterica serovar Typhimurium. J Bacteriol (2010) 1.00
Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle. Mol Genet Metab (2011) 1.00
Clinical and histologic ocular findings in pompe disease. J Pediatr Ophthalmol Strabismus (2010) 1.00
New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond. Pediatr Endocrinol Rev (2014) 0.99
Enhanced efficacy of an AAV vector encoding chimeric, highly secreted acid alpha-glucosidase in glycogen storage disease type II. Mol Ther (2006) 0.99
Efficient analysis of urinary glycosaminoglycans by LC-MS/MS in mucopolysaccharidoses type I, II and VI. Mol Genet Metab (2010) 0.98
Allantoin in human urine quantified by ultra-performance liquid chromatography-tandem mass spectrometry. Anal Biochem (2010) 0.98
Expanding the clinical spectrum of late-onset Pompe disease: dilated arteriopathy involving the thoracic aorta, a novel vascular phenotype uncovered. Mol Genet Metab (2011) 0.98
Comparison of maltose and acarbose as inhibitors of maltase-glucoamylase activity in assaying acid alpha-glucosidase activity in dried blood spots for the diagnosis of infantile Pompe disease. Genet Med (2006) 0.98
Oropharyngeal dysphagia may occur in late-onset Pompe disease, implicating bulbar muscle involvement. Neuromuscul Disord (2013) 0.98
Immune modulation in Pompe disease treated with enzyme replacement therapy. Expert Rev Clin Immunol (2012) 0.97
Resection of hepatocellular adenoma in patients with glycogen storage disease type Ia. J Hepatol (2007) 0.97
Expanding the phenotype of late-onset Pompe disease: tongue weakness: a new clinical observation. Muscle Nerve (2011) 0.97
Screening for Pompe disease using a rapid dried blood spot method: experience of a clinical diagnostic laboratory. Muscle Nerve (2009) 0.96
Newborn screening for Pompe disease: synthesis of the evidence and development of screening recommendations. Pediatrics (2007) 0.95
Characterization of in vitro antimurine thymocyte globulin-induced regulatory T cells that inhibit graft-versus-host disease in vivo. Blood (2007) 0.95